BNP Paribas Arbitrage SA lessened its holdings in Qiagen N.V. (NASDAQ:QGEN) by 10.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,475 shares of the company’s stock after selling 2,288 shares during the quarter. BNP Paribas Arbitrage SA’s holdings in Qiagen were worth $613,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also made changes to their positions in the business. Dimensional Fund Advisors LP lifted its position in shares of Qiagen by 0.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 73,215 shares of the company’s stock valued at $2,121,000 after buying an additional 306 shares during the last quarter. Russell Investments Group Ltd. lifted its position in shares of Qiagen by 19.9% during the 2nd quarter. Russell Investments Group Ltd. now owns 286,553 shares of the company’s stock valued at $9,596,000 after buying an additional 47,657 shares during the last quarter. Public Employees Retirement Association of Colorado lifted its position in shares of Qiagen by 3.5% during the 2nd quarter. Public Employees Retirement Association of Colorado now owns 7,214 shares of the company’s stock valued at $242,000 after buying an additional 246 shares during the last quarter. Sei Investments Co. lifted its position in shares of Qiagen by 47.1% during the 2nd quarter. Sei Investments Co. now owns 176,419 shares of the company’s stock valued at $5,915,000 after buying an additional 56,489 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. lifted its position in shares of Qiagen by 3.6% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 188,102 shares of the company’s stock valued at $6,308,000 after buying an additional 6,557 shares during the last quarter. Hedge funds and other institutional investors own 62.37% of the company’s stock.

A number of research analysts have recently commented on QGEN shares. TheStreet raised Qiagen from a “c+” rating to a “b+” rating in a research report on Tuesday, November 7th. Deutsche Bank reaffirmed a “buy” rating on shares of Qiagen in a research report on Wednesday, November 8th. Commerzbank reissued a “buy” rating on shares of Qiagen in a report on Tuesday, November 7th. Zacks Investment Research raised Qiagen from a “hold” rating to a “buy” rating and set a $39.00 price objective on the stock in a report on Tuesday, October 10th. Finally, Cowen reissued a “hold” rating and set a $33.00 price objective on shares of Qiagen in a report on Monday, August 14th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $34.06.

Shares of Qiagen N.V. (NASDAQ:QGEN) opened at $30.84 on Thursday. The stock has a market capitalization of $7,062.02, a PE ratio of 25.22, a P/E/G ratio of 1.90 and a beta of 1.10. The company has a debt-to-equity ratio of 0.68, a quick ratio of 4.78 and a current ratio of 5.33. Qiagen N.V. has a 1-year low of $27.51 and a 1-year high of $36.34.

Qiagen (NASDAQ:QGEN) last issued its quarterly earnings data on Monday, November 6th. The company reported $0.32 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.32. The business had revenue of $364.00 million for the quarter, compared to analysts’ expectations of $363.42 million. Qiagen had a return on equity of 11.36% and a net margin of 6.40%. The firm’s quarterly revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.29 EPS. analysts expect that Qiagen N.V. will post 1.25 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Qiagen N.V. (QGEN) Holdings Cut by BNP Paribas Arbitrage SA” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/12/07/qiagen-n-v-qgen-holdings-cut-by-bnp-paribas-arbitrage-sa.html.

About Qiagen

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Institutional Ownership by Quarter for Qiagen (NASDAQ:QGEN)

Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with MarketBeat.com's FREE daily email newsletter.